Pluristem Therapeutics Inc (PSTI)

[El Mago]

From Dr. Prather in a previous interview:
"Pluristem believes investors should be rewarded over the next 12
months from announcements surrounding discoveries and improvements in
the Company's technology, milestone announcements surrounding
Pluristem's indications for their PLX cells and clinical trial for
PLX-I, and potential collaborations. These include:
Fall 2007 – Filing of the Investigational New Drug Application (IND)
for PLX – I for enhancing the engraftment of UCB in BMT
Winter 2007 – FDA acceptance of the IND (Pluristem does not need to
hear from the FDA, 30 days after submission, if there are not
comments from the FDA, then the IND is deemed to be approved)
Winter 2007 – The announced from Pluristem of the second clinical
indication for their PLX cells.
Winter 2007 – The initiation of animal trials of Pluristem's PLX
cells for this second indication
Beginning of 2008 – The initiation of Phase I clinical trials (the
safety of PLX – I for enhancing the engraftment of UCB in BMT) at two
sites in the US"